Mast cells as therapeutic target in cancer

European Journal of Pharmacology

Volumn 778, Issue , 2016, Pages 152-157

  Ribatti, Domenico ^a,b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Anticancer agents; Mast cells; Tryptase; Tumor growth; Tyrosine kinase inhibitors

Indexed keywords

AGATOLIMOD; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AXITINIB; CROMOGLYCATE DISODIUM; DASATINIB; ENZASTAURIN; HISTAMINE H1 RECEPTOR ANTAGONIST; IMATINIB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MASITINIB; MDX 60; MIDOSTAURIN; NONSTEROID ANTIINFLAMMATORY AGENT; OBATOCLAX; OMALIZUMAB; PAZOPANIB; PROSTAGLANDIN D2; PROSTAGLANDIN D2 DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR ANTAGONIST; SILYMARIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; STEROID; SUNITINIB; TANESPIMYCIN; TOCERANIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ENZYME INHIBITION; HUMAN; MAST CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; HUMANS; MAST CELLS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84928957873     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.02.056     Document Type: Review

References (81)

1. C. Akin, and D.D. Metcalfe The biology of Kit in disease and the application of pharmacogenetics J. Allergy Clin. Immunol. 114 2004 13 19
2. M. Arock, and P. Valent Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives Expert Rev. Hematol. 3 2010 497 516
3. L. Benitez-Bribiesca, A. Wong, D. Utrera, and E. Castellanos The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix J. Histochem. Cytochem. 49 2001 1061 1062
4. R.J. Blair, H. Meng, M.J. Marchese, S. Ren, L.B. Schwartz, M.G. Tonnesen, and B.L. Gruber Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor J. Clin. Investig. 99 1997 2691 2700
5. P.F. Bowrey, J. King, C. Magarey, P. Schwartz, P. Marr, E. Bolton, and D.L. Morris Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br. J. Cancer 82 2000 167 170
6. L.M. Coussens, W.W. Raymond, G. Bergers, M. Laig-Webster, O. Behrendtsen, Z. Werb, G.H. Caughey, and D. Hanahan Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis Genes Dev. 13 1999 1382 1397
7. L.M. Coussens, C.L. Tinkle, D. Hanahan, and Z. Werb MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis Cell 103 2000 481 490
8. D.A. de Souza, V.D. Toso, M.R.d.C. Campos, V.S. Lara, C. Oliver, and M.C. Jamur Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression PLoS One 2012 7
9. A. Detoraki, R.I. Staiano, F. Granata, G. Giannattasio, N. Prevete, A. de Paulis, D. Ribatti, A. Genovese, M. Triggiani, and G. Marone Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects J. Allergy Clin. Immunol. 123 2009 1142 1149
10. P. Dubreuil, S. Letard, M. Ciufolini, L. Gros, M. Humbert, N. Casteran, L. Borge, B. Hajem, A. Lermet, W. Sippl, E. Voisset, M. Arock, C. Auclair, P.S. Leventhal, C.D. Mansfield, A. Moussy, and O. Hermine Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS One 2009 4
11. A.M. Dvorak, M.C. Mihm, J.E. Osage, and H.F. Dvorak Melanoma. An ultrastructural study of the host inflammatory and vascular responses J. Investig. Dermatol. 75 1980 388 393
12. G.O. Elpek, T. Gelen, N.H. Aksoy, A. Erdogan, L. Dertsiz, A. Demircan, and N. Keles The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus J. Clin. Pathol. 54 2001 940 944
13. C. Fitzsimons, B. Molinari, H. Duran, M. Palmieri, C. Davio, G. Cricco, R. Bergoc, and E. Rivera Atypical association of H1 and H2 histamine receptors with signal transduction pathways during multistage mouse skin carcinogenesis Inflamm. Res. 46 1997 292 298
14. N. Fukushima, T. Satoh, M. Sano, and O. Tokunaga Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma Leuk. Lymphoma 42 2001 709 720
15. K.V. Gleixner, M. Mayerhofer, K. Sonneck, A. Gruze, P. Samorapoompichit, C. Baumgartner, F.Y. Lee, K.J. Aichberger, P.W. Manley, D. Fabbro, W.F. Pickl, C. Sillaber, and P. Valent Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT Haematologica 92 2007 1451 1459
16. J. Glowacki, and J.B. Mulliken Mast cells in hemangiomas and vascular malformations Pediatrics 70 1982 48 51
17. J. Gotlib KIT mutations in mastocytosis and their potential as therapeutic targets Immunol. Allergy Clin. N. Am. 26 2006 575 592
18. J. Gotlib, C. Berube, J.D. Growney, C.C. Chen, T.I. George, C. Williams, T. Kajiguchi, J. Ruan, S.L. Lilleberg, J.A. Durocher, J.H. Lichy, Y. Wang, P.S. Cohen, D.A. Arber, M.C. Heinrich, L. Neckers, S.J. Galli, D.G. Gilliland, and S.E. Coutre Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood 106 2005 2865 2870
19. E. Gounaris, S.E. Erdman, C. Restaino, M.F. Gurish, D.S. Friend, F. Gounari, D.M. Lee, G. Zhang, J.N. Glickman, K. Shin, V.P. Rao, T. Poutahidis, R. Weissleder, K.M. McNagny, and K. Khazaie Mast cells are an essential hematopoietic component for polyp development Proc. Natl. Acad. Sci USA 104 2007 19977 19982
20. R.M. Graham, and J.B. Graham Mast cells and cancer of the cervix Surg. Gynecol. Obstet. 123 1966 3 9
21. M.A. Grimbaldeston, S. Nakae, J. Kalesnikoff, M. Tsai, and S.J. Galli Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B Nat. Immunol. 8 2007 1095 1104
22. T. Groot Kormelink, D.G. Powe, S.A. Kuijpers, A. Abudukelimu, M.H. Fens, E.H. Pieters, W.W. Kassing van der Ven, H.O. Habashy, I.O. Ellis, B.R. Blokhuis, M. Thio, W.E. Hennink, G. Storm, F.A. Redegeld, and R.M. Schiffelers Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation Oncotarget 30 2014 3159 3167
23. F. Hartveit Mast cells and metachromasia in human breast cancer: their occurrence, significance and consequence: a preliminary report J. Pathol. 134 1981 7 11
24. B. Huang, Z. Lei, G.M. Zhang, D. Li, C. Song, B. Li, Y. Liu, Y. Yuan, J. Unkeless, H. Xiong, and Z.H. Feng SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment Blood 112 2008 1269 1279
25. A. Iamaroon, S. Pongsiriwet, S. Jittidecharaks, K. Pattanaporn, S. Prapayasatok, and S. Wanachantararak Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma J. Oral Pathol. Med. 32 2003 195 199
26. A. Imada, N. Shijubo, H. Kojima, and S. Abe Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma Eur. Respir. J. 15 2000 1087 1093
27. H.J. Jeong, H.A. Oh, S.Y. Nam, N.R. Han, Y.S. Kim, J.H. Kim, S.J. Lee, M.H. Kim, P.D. Moon, H.M. Kim, and H.A. Oh The critical role of mast cell-derived hypoxia-inducible factor-1α in human and mice melanoma growth Int. J. Cancer 132 2013 2492 2501
28. I. Koskivirta, O. Rahkonen, M. Mayranpaa, S. Pakkanen, M. Husheem, A. Sainio, H. Hakovirta, J. Laine, E. Jokinen, E. Vuorio, P. Kovanen, and H. Jarvelainen Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology Histochem. Cell Biol. 126 2006 335 342
29. J. Lachter, M. Stein, C. Lichtig, S. Eidelman, and M. Munichor Mast cells in colorectal neoplasias and premalignant disorders Dis. Colon Rectum 38 1995 290 293
30. A. Le Cesne, J.Y. Blay, B.N. Bui, O. Bouche, A. Adenis, J. Domont, A. Cioffi, I. Ray-Coquard, N. Lassau, S. Bonvalot, A. Moussy, J.P. Kinet, and O. Hermine Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur. J. Cancer 46 2010 1344 1351
31. C.A. London, A.L. Hannah, R. Zadovoskaya, M.B. Chien, C. Kollias-Baker, M. Rosenberg, S. Downing, G. Post, J. Boucher, N. Shenoy, D.B. Mendel, G. McMahon, and J.M. Cherrington Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies Clin. Cancer Res. 9 2003 2755 2768
32. D.D. Metcalfe Mast cells and mastocytosis Blood 112 2008 946 956
33. D.D. Metcalfe, D. Baram, and Y.A. Mekori Mast cells Physiol. Rev. 77 1997 1033 1079
34. E. Mitry, P. Hammel, G. Deplanque, F. Mornex, P. Levy, J.F. Seitz, A. Moussy, J.P. Kinet, O. Hermine, P. Rougier, and E. Raymond Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer Cancer Chemother. Pharmacol. 66 2010 395 403
35. S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia Haematologica 92 2007 1367 1374
36. S. Molica, A. Vacca, E. Crivellato, A. Cuneo, and D. Ribatti Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia Eur. J. Haematol. 71 2003 137 139
37. J.J. Nordlund, and P.W. Askenase The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice J. Investig. Dermatol. 81 1983 28 31
38. K. Norrby, A. Jakobsson, and J. Sorbo Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 52 1986 195 206
39. K. Norrby, A. Jakobsson, and J. Sorbo Mast-cell secretion and angiogenesis, a quantitative study in rats and mice Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 57 1989 251 256
40. B. Peter, S. Cerny-Reiterer, E. Hadzijusufovic, K. Schuch, G. Stefanzl, G. Eisenwort, K.V. Gleixner, G. Hoermann, M. Mayerhofer, M. Kundi, S. Baumgartner, W.R. Sperr, W.F. Pickl, M. Willmann, and P. Valent The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells J. Leukoc. Biol. 95 2014 95 9104
41. P. Pittoni, S. Piconese, C. Tripodo, and M.P. Colombo Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors Oncogene 30 2011 757 769
42. P. Pittoni, C. Tripodo, S. Piconese, G. Mauri, M. Parenza, A. Rigoni, S. Sangaletti, and M.P. Colombo Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers Cancer Res. 71 2011 5987 5997
43. H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schoffski, A. Van Oosterom, P. Marynen, and M. Debiec-Rychter Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate Clin. Cancer Res. 12 2006 2622 2627
44. N.K. Pryer, L.B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J.M. Cherrington, and C.A. London Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors Clin. Cancer Res. 9 2003 5729 5734
45. G. Ramakrishnan, S. Jagan, S. Kamaraj, P. Anandakumar, and T. Devaki Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis Investig. New Drugs 27 2009 233 240
46. L.L. Reber, T. Marichal, and S.J. Galli New models for analyzing mast cell functions in vivo Trends Immunol. 33 2012 613 625
47. J.A. Reed, N.S. McNutt, J.K. Bogdany, and A.P. Albino Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression J. Cutan. Pathol. 23 1996 495 505
48. D. Ribatti, and E. Crivellato The controversial role of mast cells in tumor growth Int. Rev. Cell Mol. Biol. 275 2009 89 8131
49. D. Ribatti, and E. Crivellato Mast cell, angiogenesis, and cancer A.M. Gilfillan, D.D. Metcalfe (Eds.), Mast Cell Biology: Contemporary and Emerging Topics 2011 Landes Biosciences and Springer Science and Business Media New York 270 288
50. D. Ribatti, and E. Crivellato Mast cells, angiogenesis, and tumour growth Biochim. Biophys. Acta 1822 2012 2 8
51. D. Ribatti, and E. Crivellato Mast cell ontogeny: an historical overview Immunol. Lett. 159 2014 11 14
52. D. Ribatti, E. Crivellato, L. Candussio, B. Nico, A. Vacca, L. Roncali, and F. Dammacco Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane Clin. Exp. Allergy 31 2001 602 608
53. D. Ribatti, M.G. Ennas, A. Vacca, F. Ferreli, B. Nico, S. Orru, and P. Sirigu Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma Eur. J. Clin. Investig. 33 2003 420 425
54. D. Ribatti, N. Finato, E. Crivellato, D. Guidolin, V. Longo, D. Mangieri, B. Nico, A. Vacca, and C.A. Beltrami Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases Histopathology 51 2007 837 842
55. D. Ribatti, N. Finato, E. Crivellato, A. Marzullo, D. Mangieri, B. Nico, A. Vacca, and C.A. Beltrami Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer Am. J. Obstet. Gynecol. 193 2005 1961 1965
56. D. Ribatti, B. Nico, M.T. Perra, V. Longo, C. Maxia, T. Annese, F. Piras, D. Murtas, and P. Sirigu Erythropoietin is involved in angiogenesis in human primary melanoma Int. J. Exp. Pathol. 91 2010 495 499
57. D. Ribatti, B. Nico, A. Vacca, A. Marzullo, N. Calvi, L. Roncali, and F. Dammacco Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br. J. Cancer 77 1998 1900 1906
58. D. Ribatti, G. Polimeno, A. Vacca, A. Marzullo, E. Crivellato, B. Nico, G. Lucarelli, and F. Dammacco Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes Leukemia 16 2002 1680 1684
59. D. Ribatti, G. Ranieri, B. Nico, V. Benagiano, and E. Crivellato Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay Int. J. Dev. Biol. 55 2011 99 9102
60. D. Ribatti, L. Roncali, B. Nico, and M. Bertossi Effects of exogenous heparin on the vasculogenesis of the chorioallantoic membrane Acta Anat. (Basel) 130 1987 257 263
61. D. Ribatti, A. Vacca, B. Nico, F. Quondamatteo, R. Ria, M. Minischetti, A. Marzullo, R. Herken, L. Roncali, and F. Dammacco Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br. J. Cancer 79 1999 451 455
62. D. Ribatti, A. Vacca, R. Ria, A. Marzullo, B. Nico, R. Filotico, L. Roncali, and F. Dammacco Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma Eur. J. Cancer 39 2003 666 674
63. I.G. Rojas, M.L. Spencer, A. Martinez, M.A. Maurelia, and M.I. Rudolph Characterization of mast cell subpopulations in lip cancer J. Oral Pathol. Med. 34 2005 268 273
64. M. Samoszuk, and M.A. Corwin Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec) Int. J. Cancer 106 2003 647 652
65. D.D. Santos, E. Hatjiharissi, O. Tournilhac, M.Z.A. Chemaly, X. Leleu, L. Xu, C. Patterson, A.R. Branagan, R.J. Manning, A.W. Ho, Z.R. Hunter, E.A. Dimmock, J.L. Kutok, W.H. Churchill, M.C. Castells, Y.T. Tai, K.C. Anderson, and S.P. Treon CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders Clin. Lymphoma Myeloma 6 2006 478 483
66. M. Sawatsubashi, T. Yamada, N. Fukushima, H. Mizokami, O. Tokunaga, and T. Shin Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma Virchows Arch. 436 2000 243 248
67. M.M. Schittenhelm, S. Shiraga, A. Schroeder, A.S. Corbin, D. Griffith, F.Y. Lee, C. Bokemeyer, M.W.N. Deininger, B.J. Druker, and M.C. Heinrich Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Res. 66 2006 473 481
68. N.P. Shah, F.Y. Lee, R. Luo, Y. Jiang, M. Donker, and C. Akin Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood 108 2006 286 291
69. F. Siebenhaar, M. Metz, and M. Maurer Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model Exp. Dermatol. 23 2014 159 164
70. J. Sorbo, A. Jakobsson, and K. Norrby Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2 Int. J. Exp. Pathol. 75 1994 43 50
71. L. Soucek, E.R. Lawlor, D. Soto, K. Shchors, L.B. Swigart, and G.I. Evan Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors Nat. Med. 13 2007 1211 1218
72. J.R. Starkey, P.K. Crowle, and S. Taubenberger Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis Int. J. Cancer 42 1988 48 52
73. I. Takanami, K. Takeuchi, and M. Naruke Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma Cancer 88 2000 2686 2692
74. A. Tanaka, Y. Yamane, and H. Matsuda Mast cell MMP-9 production enhanced by bacterial lipopolysaccharide J. Vet. Med. Sci. 63 2001 811 813
75. M. Tomita, Y. Matsuzaki, and T. Onitsuka Effect of mast cells on tumor angiogenesis in lung cancer Ann. Thorac. Surg. 69 2000 1686 1690
76. R. Toth-Jakatics, S. Jimi, S. Takebayashi, and N. Kawamoto Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor Hum. Pathol. 31 2000 955 960
77. E. Ullah, A.H. Nagi, and R.A. Lail Angiogenesis and mast cell density in invasive pulmonary adenocarcinoma J. Cancer Res. Ther. 8 2012 537 541
78. S.E. Ullrich, D.X. Nghiem, and P. Khaskina Suppression of an established immune response by UVA: a critical role for mast cells Photochem. Photobiol. 83 2007 1095 1100
79. C. Ustun, D.L. DeRemer, and C. Akin Tyrosine kinase inhibitors in the treatment of systemic mastocytosis Leukoc. Res. 35 2011 1143 1152
80. N. von Bubnoff, S.H.P. Gorantla, R.K. Kancha, F. Lordick, C. Peschel, and J. Duyster The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 Leukemia 19 2005 1670 1671
81. H. Yano, M. Kinuta, H. Tateishi, Y. Nakano, S. Matsui, T. Monden, J. Okamura, M. Sakai, and S. Okamoto Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis Gastric Cancer 2 1999 26 32